Genentech announces results from pertuzumab studies on HER2-positive breast cancer

[News]

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

More... (http://www.news-medical.net/news/20111130/Genentech-announces-results-from-pertuzumab-studies-on-HER2-positive-breast-cancer.aspx)

[kykeon22]

I was just wondering, if pertuzumab get approved, it will be approved for second line and beyond as well?